Making News
-
Monderer Design Creates New Vision for Ocata Therapeutics
November 16, 2014 | Announcements
CAMBRIDGE, MA (November 17, 2014) - Monderer Design, a Cambridge, MA branding and graphic design firm, has completed the rebranding of Ocata Therapeutics (OTCBB: OCAT). Ocata Therapeutics, formerly called Advanced Cell Technology, based in Marlborough, changed its name to reflect the Company's focus on Regenerative Ophthalmology™ –– the development of regenerative cell therapeutics for the treatment of ophthalmic diseases. "Ocata" is a Native American name for "healer," a term associated with repair and regeneration as opposed to merely slowing the progression of disease, or treatment of symptoms.
Monderer Design was tasked to develop a new corporate identity, collateral and responsive website to support their rebranding effort.
Dr. Paul Wotton, President and CEO of Ocata Therapeutics, said: "This is a time of transformation for our company as we continue to advance our technology leadership position in Regenerative Ophthalmology. With that, we determined it was important to select a company name that best reflects our focus going forward. As we prepare to initiate Phase 2 clinical trials for Stargardt's macular degeneration (SMD) and dry age-related macular degeneration (AMD), we are positioning Ocata to lead the way in developing safe and effective therapies for those suffering from either disease." There are currently no approved treatments for either disease.
The new website and identity can be viewed at www.ocata.com
Monderer Design provides expertise in identity design, corporate branding, collateral, website, trade show and special event, advertising and marketing program communications to visionary organizations. Our clients include: Thermo Fisher Scientific, Seres Health, New England Biolabs, Canaccord Genuity, Altisource, Viewfinity, Talend, Harvard Business School and MIT Sloan among others. For more information: www.monderer.com